CompanyGraph
Yunnan Baiyao Group Co., Ltd.
000538 · SZSE · China
Makes the only legally permitted version of Baiyao, a wound-stopping medicine whose formula the Chinese government classifies as a state secret.
Yunnan Baiyao Group holds the sole authorisation to manufacture the Baiyao hemostatic formula, a preparation that the Chinese government classifies as a state secret, meaning its full ingredient list and preparation method are legally inaccessible to anyone else — no competitor can obtain them through litigation, reverse engineering, or money. Because the formula cannot be fully disclosed, production cannot be handed to a contract manufacturer or automated away; a small group of government-cleared individuals must personally oversee the critical steps, so output is capped not by factory capacity or investment but by how many authorised people exist. That same classification blocks any generic version from reaching pharmacy shelves, and Chinese military procurement rules name Baiyao specifically, so a field unit cannot simply switch to a cheaper alternative — someone in government has to formally approve the substitution first. The entire structure rests on one administrative decision: if Chinese authorities ever revoke the exclusive manufacturing authorisation or reclassify the formula out of state-secret status, every barrier dissolves at once.
How does this company make money?
The company sells packaged Baiyao products — powders, capsules, and similar formats — through Chinese pharmacy chains, hospital systems, and e-commerce platforms, collecting revenue on each unit sold. Because no competitor can legally make the same product, the company can price at a premium rather than competing on cost.
What makes this company hard to replace?
Because the Baiyao formula is a state secret, no generic or bioequivalent version can legally be made or sold, so there is simply no comparable product on the shelf to switch to. Traditional Chinese Medicine practitioners risk their professional credibility if they substitute a non-traditional treatment for one that is deeply embedded in standard practice. Chinese military units face the most concrete barrier of all: their procurement rules name Baiyao specifically, so switching to anything else requires formal government approval, not just a decision by a purchasing officer.
What limits this company?
The number of people authorised to access the classified formula and supervise its preparation is small, and the government controls who gets that access — not the company. Hiring more staff or spending more money does not open the bottleneck, because clearance comes from the state, not from internal training.
What does this company depend on?
The company cannot operate without medicinal herb supply chains from Yunnan province, manufacturing licences issued by China National Medical Products Administration, the state-secret formula access authorisation granted by the Chinese government, the small group of traditional preparation knowledge holders who oversee core production steps, and modern pharmaceutical production facilities that meet GMP standards.
Who depends on this company?
Chinese military and paramilitary units rely on Baiyao powder as their standard battlefield bleeding-control agent and would lose that supply if the company stopped. Traditional Chinese Medicine practitioners would lose the primary hemostatic remedy they prescribe. Chinese consumers treating cuts and minor wounds at home would lose what many consider their culturally preferred product over Western alternatives.
How does this company scale?
Brand recognition and distribution relationships across Chinese pharmacy chains, hospital systems, and e-commerce platforms can be extended to new product categories and new geographic markets without major additional cost. What cannot scale at the same pace is the core Baiyao preparation itself — the number of authorised individuals who must directly oversee production is fixed by government clearance, so that part of the operation grows slowly no matter how fast the rest of the business expands.
What external forces can significantly affect this company?
Chinese government policies on Traditional Chinese Medicine promotion and state-secret classification regimes could change the rules around formula access or manufacturing requirements at any time. Rising labour costs in China put pressure on preparation methods that cannot be fully automated. In export markets, international regulators typically require separate clinical validation for TCM-based products, creating a barrier that must be cleared country by country.
Where is this company structurally vulnerable?
If Chinese state authorities either revoked the company's exclusive manufacturing authorisation or removed the Baiyao formula from state-secret classification, the legal wall would come down entirely. Competitors could then access the formula, apply for their own manufacturing licences, and sell into the same markets — including to the military, which would no longer need special approval to switch suppliers.